![Benjamin Yerxa](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Benjamin Yerxa
President at
OPUS GENETICS, INC.
Net worth: 3 M $ as of 2026-05-30
Profile
Benjamin R.
Yerxa was the founder of Opus Genetics, Inc. (2021, Chief Executive Officer 2022-2024) and Envisia Therapeutics, Inc. (2013, President 2013-2017).
Current jobs include Chairman at RainBio, Inc., Independent Director at Clearside Biomedical, Inc. (2022), Director at The North Carolina Biotechnology Center (2008), Director at Vedere Bio II, Inc., President & Director at Opus Genetics, Inc. (2024), and Director at Nacuity Pharmaceuticals, Inc. (2019).
Former jobs include Chief Executive Officer at The Foundation Fighting Blindness, Inc. (2017-2022), Chief Executive Officer at Retinal Degeneration Fund (2018-2022), Director at SparingVision SAS (2017-2022), EVP, Chief Research & Development Officer at Inspire Pharmaceuticals, Inc. (2009-2010), Research Scientist at Burroughs Wellcome, Vice President-Product Development at Parion Sciences, Inc. (2010-2011), Vice President-Research & Development at Clearside Biomedical, Inc. (2011-2012), and Chief Scientific Officer at Liquidia Technologies, Inc. (2012-2015).
Education includes a doctorate from the University of California, Irvine (1993) and an undergraduate degree from the University of California San Diego (1988).
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
OPUS GENETICS, INC. 0.87% | 2026-04-22 | 711,535 ( 0.87% ) | 3 M $ | 2026-05-30 |
Benjamin Yerxa active positions
| Companies | Position | Start |
|---|---|---|
| CLEARSIDE BIOMEDICAL, INC. | Director/Board Member | 2022-03-02 |
| OPUS GENETICS, INC. | President | 2024-10-21 |
Nacuity Pharmaceuticals, Inc.
 Nacuity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Director/Board Member | 2019-09-30 |
RainBio, Inc.
 RainBio, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapy for corneal treatments | Chairman | - |
Vedere Bio II, Inc.
 Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Develops ocular gene therapy | Director/Board Member | - |
The North Carolina Biotechnology Center
 The North Carolina Biotechnology Center Internet Software/ServicesTechnology Services Provides research and education grants | Director/Board Member | 2010-10-31 |
Former positions of Benjamin Yerxa
| Companies | Position | End |
|---|---|---|
Opus Genetics, Inc.
 Opus Genetics, Inc. BiotechnologyHealth Technology Provides clinical stage gene therapies for inherited retinal diseases | Chief Executive Officer | 2023-12-31 |
Retinal Degeneration Fund
 Retinal Degeneration Fund Investment Trusts/Mutual FundsMiscellaneous Operates as a fund focuses on making mission-related investments in companies with projects nearing clinical testing | Chief Executive Officer | 2022-06-30 |
The Foundation Fighting Blindness, Inc.
 The Foundation Fighting Blindness, Inc. Miscellaneous Commercial ServicesCommercial Services Provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome | Chief Executive Officer | 2022-06-30 |
| ░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
Training of Benjamin Yerxa
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
60
1st degree connections
17
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 17 |
|---|---|
Inspire Pharmaceuticals, Inc.
 Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes ophthalmic products | Health Technology |
Parion Sciences, Inc.
 Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new treatments for serious diseases in multiple therapeutic areas | Commercial Services |
Liquidia Technologies, Inc.
 Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Develops particle-based vaccines and therapeutics for prevention and treatment of human disease | Health Technology |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California San Diego
 University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The North Carolina Biotechnology Center
The North Carolina Biotechnology Center Internet Software/ServicesTechnology Services Provides research and education grants | Technology Services |
The Foundation Fighting Blindness, Inc.
The Foundation Fighting Blindness, Inc. Miscellaneous Commercial ServicesCommercial Services Provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome | Commercial Services |
Burroughs Wellcome | |
Clearside Biomedical, Inc.
 Clearside Biomedical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures suprachoroidal space injections for eye diseases | Health Technology |
Envisia Therapeutics, Inc.
 Envisia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ocular therapies | Health Technology |
Nacuity Pharmaceuticals, Inc.
Nacuity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Health Technology |
SparingVision SAS
 SparingVision SAS BiotechnologyHealth Technology Develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa | Health Technology |
Retinal Degeneration Fund
Retinal Degeneration Fund Investment Trusts/Mutual FundsMiscellaneous Operates as a fund focuses on making mission-related investments in companies with projects nearing clinical testing | Miscellaneous |
Ocuphire Pharma, Inc.
 Ocuphire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceuticals for eye disorders | Health Technology |
RainBio, Inc.
RainBio, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapy for corneal treatments | Health Technology |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Develops ocular gene therapy | Commercial Services |
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Provides clinical stage gene therapies for inherited retinal diseases | Health Technology |
- Stock Market
- Insiders
- Benjamin Yerxa
